Abstract
Human myeloid leukemia cells have a growth advantage over normal cells because they do not differentiate into functional end-cells but remain in the proliferative pool. Several agents have been identified as inducers of differentiation of leukemia cells; among them are the retinoids, 1 alpha,25-dihydroxyvitamin D3 and human tumor necrosis factor alpha, which will be discussed in the following chapter.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Aged, 80 and over
-
Animals
-
Calcitriol / pharmacology
-
Calcitriol / therapeutic use
-
Cell Differentiation / drug effects
-
Clinical Trials as Topic
-
Humans
-
Leukemia, Experimental / drug therapy
-
Leukemia, Myeloid, Acute / drug therapy
-
Leukemia, Myeloid, Acute / pathology*
-
Mice
-
Middle Aged
-
Myelodysplastic Syndromes / drug therapy
-
Recombinant Proteins / therapeutic use
-
Retinoids / pharmacology
-
Retinoids / therapeutic use*
-
Tretinoin / therapeutic use
-
Tumor Cells, Cultured / drug effects
-
Tumor Necrosis Factor-alpha / pharmacology
-
Tumor Necrosis Factor-alpha / therapeutic use
Substances
-
Recombinant Proteins
-
Retinoids
-
Tumor Necrosis Factor-alpha
-
Tretinoin
-
Calcitriol